FDA 'Nucs' Idenix with '963 Safety Data Request
By Marie Powers
Friday, June 21, 2013
Idenix Pharmaceuticals Inc. suffered yet another blow in the development of its hepatitis C virus (HCV) drug pipeline, as the FDA requested additional preclinical safety data for IDX20963 ('963), the company's lead uridine nucleotide prodrug.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.